Leqembi (lecanemab) was approved by the FDA in 2023. It is an infusion drug that has been shown to reduce Alzheimer’s-related cognitive decline by up to 27%. 

Mastering the art of effective prompts has become a coveted skill in the fast-growing field of AI. 

Experts have suggested the emerging technology could be a “pivotal” tool for the future of breast cancer detection. 

Gadoquatrane is now set to go through the regulatory review process on its trek to earning full FDA approval.